Biomimetic nanocomplexes loading with evolocumab and curcumin for synergistic anti-atherosclerosis therapy in ApoE−/− mice
Abstract Atherosclerosis (AS), a leading contributor to global cardiovascular mortality, is primarily driven by the dual pathological processes of chronic persistent inflammation and dysregulated lipid metabolism. Current clinical interventions are predominantly limited to single-target approaches (...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-06-01
|
| Series: | Journal of Nanobiotechnology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12951-025-03444-5 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849331649286766592 |
|---|---|
| author | Yi Liu Shengchao Ma Feng Li Hanshuang Ding Qi Zhang Feifei Yu Huiping Zhang Yinju Hao Bin Liu Yideng Jiang |
| author_facet | Yi Liu Shengchao Ma Feng Li Hanshuang Ding Qi Zhang Feifei Yu Huiping Zhang Yinju Hao Bin Liu Yideng Jiang |
| author_sort | Yi Liu |
| collection | DOAJ |
| description | Abstract Atherosclerosis (AS), a leading contributor to global cardiovascular mortality, is primarily driven by the dual pathological processes of chronic persistent inflammation and dysregulated lipid metabolism. Current clinical interventions are predominantly limited to single-target approaches (e.g., lipid-lowering therapies), which are insufficient for simultaneously modulating the two pathophysiological mechanisms and inhibiting atherosclerotic progression. Recently, combination therapeutic strategies based on multi-target and multi-organ synergistic effects have gained increasing attention in AS treatment. In this study, we developed a dual-functional nanodelivery system co-encapsulating PCSK9 inhibitor of evolocumab and natural anti-inflammatory agent of curcumin, with surface modification using macrophage membranes (Møm) and hyaluronic acid (HA). This novel design not only confers immune evasion capability to the nanocomplex but also facilitates drug accumulation in atherosclerotic lesions and hepatic tissues, thereby enabling synchronous regulation of the inflammatory microenvironment and lipid metabolic homeostasis. In vivo studies demonstrated remarkable therapeutic efficacy of this nanoformulation on atherosclerosis by effectively reducing plaque area, enhancing plaque stability and markedly ameliorating hepatic lipid accumulation. Overall, the proposed strategy, which enables multi-target and multi-organ synergistic regulation of inflammatory responses and lipid metabolism disorder, provides a promising approach for the clinical management of atherosclerosis. |
| format | Article |
| id | doaj-art-82e05f329c324da384d140fe72b3aef7 |
| institution | Kabale University |
| issn | 1477-3155 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | BMC |
| record_format | Article |
| series | Journal of Nanobiotechnology |
| spelling | doaj-art-82e05f329c324da384d140fe72b3aef72025-08-20T03:46:27ZengBMCJournal of Nanobiotechnology1477-31552025-06-0123112310.1186/s12951-025-03444-5Biomimetic nanocomplexes loading with evolocumab and curcumin for synergistic anti-atherosclerosis therapy in ApoE−/− miceYi Liu0Shengchao Ma1Feng Li2Hanshuang Ding3Qi Zhang4Feifei Yu5Huiping Zhang6Yinju Hao7Bin Liu8Yideng Jiang9Department of Pathophysiology, School of Basic Medical Sciences, Ningxia Medical UniversityDepartment of Pathophysiology, School of Basic Medical Sciences, Ningxia Medical UniversityGeneral Hospital of Ningxia Medical UniversityNHC Key Laboratory of Metabolic Cardiovascular Diseases Research, Ningxia Medical UniversityNHC Key Laboratory of Metabolic Cardiovascular Diseases Research, Ningxia Medical UniversityDepartment of Pathophysiology, School of Basic Medical Sciences, Ningxia Medical UniversityGeneral Hospital of Ningxia Medical UniversityNHC Key Laboratory of Metabolic Cardiovascular Diseases Research, Ningxia Medical UniversityDepartment of Pathophysiology, School of Basic Medical Sciences, Ningxia Medical UniversityDepartment of Pathophysiology, School of Basic Medical Sciences, Ningxia Medical UniversityAbstract Atherosclerosis (AS), a leading contributor to global cardiovascular mortality, is primarily driven by the dual pathological processes of chronic persistent inflammation and dysregulated lipid metabolism. Current clinical interventions are predominantly limited to single-target approaches (e.g., lipid-lowering therapies), which are insufficient for simultaneously modulating the two pathophysiological mechanisms and inhibiting atherosclerotic progression. Recently, combination therapeutic strategies based on multi-target and multi-organ synergistic effects have gained increasing attention in AS treatment. In this study, we developed a dual-functional nanodelivery system co-encapsulating PCSK9 inhibitor of evolocumab and natural anti-inflammatory agent of curcumin, with surface modification using macrophage membranes (Møm) and hyaluronic acid (HA). This novel design not only confers immune evasion capability to the nanocomplex but also facilitates drug accumulation in atherosclerotic lesions and hepatic tissues, thereby enabling synchronous regulation of the inflammatory microenvironment and lipid metabolic homeostasis. In vivo studies demonstrated remarkable therapeutic efficacy of this nanoformulation on atherosclerosis by effectively reducing plaque area, enhancing plaque stability and markedly ameliorating hepatic lipid accumulation. Overall, the proposed strategy, which enables multi-target and multi-organ synergistic regulation of inflammatory responses and lipid metabolism disorder, provides a promising approach for the clinical management of atherosclerosis.https://doi.org/10.1186/s12951-025-03444-5AtherosclerosisInflammationLipid metabolismNanodelivery systemEvolocumabCurcumin |
| spellingShingle | Yi Liu Shengchao Ma Feng Li Hanshuang Ding Qi Zhang Feifei Yu Huiping Zhang Yinju Hao Bin Liu Yideng Jiang Biomimetic nanocomplexes loading with evolocumab and curcumin for synergistic anti-atherosclerosis therapy in ApoE−/− mice Journal of Nanobiotechnology Atherosclerosis Inflammation Lipid metabolism Nanodelivery system Evolocumab Curcumin |
| title | Biomimetic nanocomplexes loading with evolocumab and curcumin for synergistic anti-atherosclerosis therapy in ApoE−/− mice |
| title_full | Biomimetic nanocomplexes loading with evolocumab and curcumin for synergistic anti-atherosclerosis therapy in ApoE−/− mice |
| title_fullStr | Biomimetic nanocomplexes loading with evolocumab and curcumin for synergistic anti-atherosclerosis therapy in ApoE−/− mice |
| title_full_unstemmed | Biomimetic nanocomplexes loading with evolocumab and curcumin for synergistic anti-atherosclerosis therapy in ApoE−/− mice |
| title_short | Biomimetic nanocomplexes loading with evolocumab and curcumin for synergistic anti-atherosclerosis therapy in ApoE−/− mice |
| title_sort | biomimetic nanocomplexes loading with evolocumab and curcumin for synergistic anti atherosclerosis therapy in apoe mice |
| topic | Atherosclerosis Inflammation Lipid metabolism Nanodelivery system Evolocumab Curcumin |
| url | https://doi.org/10.1186/s12951-025-03444-5 |
| work_keys_str_mv | AT yiliu biomimeticnanocomplexesloadingwithevolocumabandcurcuminforsynergisticantiatherosclerosistherapyinapoemice AT shengchaoma biomimeticnanocomplexesloadingwithevolocumabandcurcuminforsynergisticantiatherosclerosistherapyinapoemice AT fengli biomimeticnanocomplexesloadingwithevolocumabandcurcuminforsynergisticantiatherosclerosistherapyinapoemice AT hanshuangding biomimeticnanocomplexesloadingwithevolocumabandcurcuminforsynergisticantiatherosclerosistherapyinapoemice AT qizhang biomimeticnanocomplexesloadingwithevolocumabandcurcuminforsynergisticantiatherosclerosistherapyinapoemice AT feifeiyu biomimeticnanocomplexesloadingwithevolocumabandcurcuminforsynergisticantiatherosclerosistherapyinapoemice AT huipingzhang biomimeticnanocomplexesloadingwithevolocumabandcurcuminforsynergisticantiatherosclerosistherapyinapoemice AT yinjuhao biomimeticnanocomplexesloadingwithevolocumabandcurcuminforsynergisticantiatherosclerosistherapyinapoemice AT binliu biomimeticnanocomplexesloadingwithevolocumabandcurcuminforsynergisticantiatherosclerosistherapyinapoemice AT yidengjiang biomimeticnanocomplexesloadingwithevolocumabandcurcuminforsynergisticantiatherosclerosistherapyinapoemice |